FDA Approves AstraZeneca's Truqap as First Targeted Treatment for PTEN-Deficient Prostate Cancer
AZN sits 37% above its 52-week low of $131.03.
Summary
AstraZeneca's Truqap has received US FDA approval for PTEN-deficient metastatic prostate cancer, becoming the first targeted treatment for this aggressive disease. This approval is based on positive Phase III trial results demonstrating significant clinical benefit.
Key Events · Product Development and Regulatory · AZN
-
US FDA Approval for Truqap
AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone received US FDA approval for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.
-
First-in-Class Targeted Treatment
Truqap is approved as the first and only targeted treatment for this specific, aggressive form of prostate cancer, which affects approximately one in four patients with mAPMN/S prostate cancer.
-
Significant Clinical Benefit
The approval is based on the CAPItello-281 Phase III trial, which showed a statistically significant 19% reduction in the risk of radiographic disease progression or death, with a 7.5-month improvement in median radiographic progression-free survival.
-
Companion Diagnostic Approved
Concurrently, the FDA also approved a companion diagnostic test to detect PTEN deficiency in prostate adenocarcinoma tumors, enabling targeted patient selection.
Analysis · AZN · Life Sciences
The US FDA approval of Truqap for PTEN-deficient metastatic prostate cancer is a significant milestone. This marks the first and only targeted treatment for an aggressive form of prostate cancer, addressing a critical unmet need for approximately 35,000 US patients annually. The approval, based on strong Phase III data showing a 19% reduction in disease progression or death, reinforces AstraZeneca's leadership in oncology and expands its market presence in a major cancer indication.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $179.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $277.2B. The 52-week trading range was $131.03 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.